Skip to main content

Colorectal Adenoma

4
Pipeline Programs
6
Companies
7
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
3
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 6 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
1
CelecoxibPhase 3Small Molecule1 trial
CelecoxibPhase 2Small Molecule1 trial
Active Trials
NCT00582660Completed40Est. Jun 2008
NCT00141193Completed1,561Est. May 2007
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
MK0966; Rofecoxib / Duration of Treatment: 156 weeksPhase 3
MSD
MSDIreland - Ballydine
1 program
1
MK0966; Rofecoxib / Duration of Treatment: 156 weeksPhase 31 trial
Active Trials
NCT00282386Completed2,586Est. Sep 2004
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
ColonoscopyN/A1 trial
Clostridium butyricum capsules, LivePHASE_41 trial
Active Trials
NCT03663062CompletedEst. Jun 2019
NCT07167342Not Yet RecruitingEst. Oct 2030
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
2 programs
Shenbai GranulesN/A1 trial
Shenbai GranulesN/A1 trial
Active Trials
NCT07123116Not Yet Recruiting450Est. Nov 2028
NCT07129499Not Yet Recruiting450Est. Nov 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
City TherapeuticsClostridium butyricum capsules, Live
PfizerCelecoxib
MSDMK0966; Rofecoxib / Duration of Treatment: 156 weeks
PfizerCelecoxib
UNION therapeuticsShenbai Granules
UNION therapeuticsShenbai Granules
City TherapeuticsColonoscopy

Clinical Trials (7)

Total enrollment: 5,087 patients across 7 trials

NCT07167342City TherapeuticsClostridium butyricum capsules, Live

The Effect of Oral Clostridium Butyricum on the Recurrence After Colonoscopic Resection of Colorectal Adenoma

Start: Oct 2025Est. completion: Oct 2030
Phase 4Not Yet Recruiting
NCT00141193PfizerCelecoxib

Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)

Start: Feb 2001Est. completion: May 20071,561 patients
Phase 3Completed
NCT00282386MSDMK0966; Rofecoxib / Duration of Treatment: 156 weeks

A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122)

Start: Dec 1999Est. completion: Sep 20042,586 patients
Phase 3Completed
NCT00582660PfizerCelecoxib

Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib

Start: Dec 2001Est. completion: Jun 200840 patients
Phase 2Completed
NCT07123116UNION therapeuticsShenbai Granules

Shenbai Granules for Preventing Recurrence of Low-Risk Colorectal Adenomas

Start: Aug 2025Est. completion: Nov 2028450 patients
N/ANot Yet Recruiting
NCT07129499UNION therapeuticsShenbai Granules

Shenbai Granules for Preventing Malignant Transformation of High-risk Colorectal Adenomas

Start: Aug 2025Est. completion: Nov 2028450 patients
N/ANot Yet Recruiting
NCT03663062City TherapeuticsColonoscopy

ObeSity Related Colorectal Adenoma Risk

Start: Dec 2017Est. completion: Jun 2019
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

3 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.